A detailed history of Stanley Druckenmiller (Duquesne Family Office LLC) transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Duquesne Family Office LLC holds 387,400 shares of SLN stock, worth $3.17 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
387,400
Previous 387,400 -0.0%
Holding current value
$3.17 Million
Previous $7.36 Million 4.32%
% of portfolio
0.24%
Previous 0.25%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$17.39 - $26.25 $6.74 Million - $10.2 Million
387,400 New
387,400 $8.37 Million

Others Institutions Holding SLN

About Silence Therapeutics plc


  • Ticker SLN
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,888,400
  • Market Cap $294M
  • Description
  • Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...
More about SLN
Track Stanley Druckenmiller's Portfolio

Track Stanley Druckenmiller Portfolio

Follow Stanley Druckenmiller (Duquesne Family Office LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Duquesne Family Office LLC, based on Form 13F filings with the SEC.

News

Stay updated on Duquesne Family Office LLC and Stanley Druckenmiller with notifications on news.